Steven Cohen Vir Biotechnology, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 5,215 shares of VIR stock, worth $38,591. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,215

Previous 17,600 70.37%

Holding current value

$38,591

Previous $156,000 75.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.26 - $10.7 $89,915 - $132,519	-12,385 Reduced 70.37%	5,215 $39,000
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $113,687 - $188,634	-14,900 Reduced 45.85%	17,600 $156,000
Q1 2024 May 15, 2024	BUY	$8.6 - $11.9 $210,700 - $291,550	24,500 Added 306.25%	32,500 $329,000
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $38,024 - $50,420	4,900 Added 158.06%	8,000 $80,000
Q3 2023 Nov 14, 2023	SELL	$9.14 - $24.62 $4.65 Million - $12.5 Million	-508,500 Reduced 99.39%	3,100 $29,000
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $27.2 Million - $32 Million	-1,171,500 Reduced 69.6%	511,600 $12.5 Million
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $37.5 Million - $51.9 Million	1,683,100 New	1,683,100 $39.2 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $995,096 - $1.69 Million	54,496 New	54,496 $1.05 Million
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $43.5 Million - $82.2 Million	-2,055,100 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $63 Million - $110 Million	2,033,400 Added 9370.51%	2,055,100 $86 Million
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $757,330 - $1.18 Million	21,700 New	21,700 $944,000

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account